EMRACLIDINE, EMRACLIDINE, EMRACLIDINE clinical trials

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia

This study is looking at a new medicine called Emraclidine for adults with schizophrenia over 52 weeks. It aims to see if the medicine is safe and if people can take it for a long time without too many problems.